期刊文献+

Partial Protection by Lipoic Acid Against Carboplantin-induced Ototoxicity in Rats 被引量:3

Partial Protection by Lipoic Acid Against Carboplantin-induced Ototoxicity in Rats
下载PDF
导出
摘要 Objective To investigate the alterations in auditory brainstem evoked responses (ABRs) and the changes of carboplatin-induced ototoxicity in the cochlear oxidant/antioxidant systems and otoprotection by an antioxidant lipoate. Methods Male wistar rats were divided into four groups and treated as follows: 1) vehicle (saline) control, 2) carboplatin (256 mg/kg, i.p.), 3) lipoate (100 mg/kg, i.p.), 4) lipoate + carboplatin. Post-treatment ABRs were performed after four days and rats were sacrificed with their cochleae harvested and analyzed. Results Carboplatin significantly elevated ABR threshold above the pretreatment thresholds. Lipoate+carboplatin treated rats showed decreased elevation of hearing threshold. Carboplatin significantly depleted cochlear reduced to oxizized glutathione (GSH/GSSG) ratio, whereas lipoate+carboplatin treatment increased GSH/GSSG ratio. Carboplatin significantly decreased cochlear copper zinc-superoxide dismutase (CuZn-SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR) and glutathione-S-transferase (GST) activities and enzyme protein expressions and a significant increase in Mn-SOD activity, protein expression and malondialdehyde (MDA) level. Cochlear antioxidant enzyme activities, enzyme protein expressions and MDA level were partially restored in lipoate+carboplatin treated rats, compared to carboplatin alone. Conclusion Carboplatin-induced ototoxicity is related to impairment of cochlear antioxidant system and otoprotection conferred by lipoate is associated with partial sparing of the cochlear antioxidant defense system. Objective To investigate the alterations in auditory brainstem evoked responses (ABRs) and the changes of carboplatin-induced ototoxicity in the cochlear oxidant/antioxidant systems and otoprotection by an antioxidant lipoate. Methods Male wistar rats were divided into four groups and treated as follows: 1) vehicle (saline) control, 2) carboplatin (256 mg/kg, i.p.), 3) lipoate (100 mg/kg, i.p.), 4) lipoate + carboplatin. Post-treatment ABRs were performed after four days and rats were sacrificed with their cochleae harvested and analyzed. Results Carboplatin significantly elevated ABR threshold above the pretreatment thresholds. Lipoate+carboplatin treated rats showed decreased elevation of hearing threshold. Carboplatin significantly depleted cochlear reduced to oxizized glutathione (GSH/GSSG) ratio, whereas lipoate+carboplatin treatment increased GSH/GSSG ratio. Carboplatin significantly decreased cochlear copper zinc-superoxide dismutase (CuZn-SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR) and glutathione-S-transferase (GST) activities and enzyme protein expressions and a significant increase in Mn-SOD activity, protein expression and malondialdehyde (MDA) level. Cochlear antioxidant enzyme activities, enzyme protein expressions and MDA level were partially restored in lipoate+carboplatin treated rats, compared to carboplatin alone. Conclusion Carboplatin-induced ototoxicity is related to impairment of cochlear antioxidant system and otoprotection conferred by lipoate is associated with partial sparing of the cochlear antioxidant defense system.
机构地区 Departments of Surgery
出处 《Biomedical and Environmental Sciences》 SCIE CAS CSCD 2005年第3期198-206,共9页 生物医学与环境科学(英文版)
基金 This work was supported in part by the Central Research Committee (CRC) Grant of SIU School of Medicine.
关键词 CARBOPLATIN Alpha-lipoic acid OTOTOXICITY ANTIOXIDANTS RATS Carboplatin Alpha-lipoic acid Ototoxicity Antioxidants Rats
  • 相关文献

参考文献40

  • 1Steiner, H., Holtl, L., Wirtenberger, W., Berger, A. P., Bartsch, G., and Hobisch, A. (2002). Long term experience with carboplatin monotherapy for clinical stage I seminoma: a retrospective single center study. Urology 60, 324-328.
  • 2Ettinger, D. S. (1998). The role of carboplatin in the treatment of small-cell lung cancer. Oncology (Huntingt) 12, 36-43.
  • 3Cavaletti, G., Bogliun, G., Zincone, A., Marzorati, L., Melzi, P., Frattola, L., Marzola, M., Bonazzi, C., Cantu, M. G., Chiari, S., Galli, A., Bregni, M., and Gianni, M. (1998). Neuro and ototoxicity of high dose carboplatin treatment in poor prognosis ovarian cancer patients. Anticancer Res. 18, 3797-3802.
  • 4Bohm, S., Oriana, S., Spatti, G., DiRe, F., Breasciani, G., Pirovano, C., Grosso, I., Martini, C., Caraceni, A., Pilotti, S., and Zunini, F. (1999). Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma. Oncology 57, 115-120.
  • 5Wandt, H., Birkmann, J., Denzel, T., Schafer, K., Schwab, G., Pilz, D., Egger, H., Both, A., and Gallmeir, W. M. (1999). Sequential cycles of high dose chemotherapy with dose escalation carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer. Bone Marrow Transplant 23, 763-770.
  • 6Simon, T., Hero, B., Dupuis, W., Selle, B., and Berthold, F. (2002). The incidence if hearing impairment after successful treatment of neuroblastoma. Klin. Padiatr. 214, 149-152.
  • 7Obermair, A., Speiser, P., Thoma, M., Kaider, A., Salzer, H., Dittrich, C., and Sevelda, R. (1998). Prediction of toxicity but not of clinical course by determining carboplatin exposure in patients with epithelial ovarian cancer treated with a combination of carboplatin and cisplatin. Int. J. Oncol. 13, 1023-1030.
  • 8Neuwelt, E. A., Brummet, R. E., Doolittle, N. D., Maldoon, L. L., Kroll, R. A., Pagel, M. A., Dojan, R., Church, V., Remsen, L. G., and Bubalo, J. S. (1998). First evidence of otoprotection against caboplatin-induced hearing loss with a two compartment system in patient with central nervous system malignancy using sodium thiosulfate. J. Pharmacol. Exp. Therap. 286, 77-84.
  • 9Husain, K., Scott, R. B., Whitworth, C., Somani, S. M., and Rybak, L. P. (2001a). Dose response of carboplatin-induced hearing loss in rats: antioxidant defense system. Hear. Res. 151, 71-78.
  • 10Hu, B. H., McFadden, S. L., Salvi, R. J., and Henderson, D. (1999). Intracochlear infusion of buthionine sulfoximine potentiates carboplatin ototoxicity in the chinchilla. Hear. Res. 128, 125-134.

同被引文献15

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部